Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection

William Harford, Frank Lanza, Ajit Arora, David Graham, Marian Haber, Alice Weissfeld, Pamela Rose, Nancy Siepman

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background. Treatment with amoxicillin plus omeprazole results in disappointing cure rates of Helicobacter pylori infection. The minimal inhibitory concentration of lansoprazole for H. pylori in vitro is lower than that for omeprazole, prompting interest in treatment with amoxicillin plus lansoprazole. Materials and Methods. H. pylori-infected patients with endoscopically documented duodenal ulcer either currently or within the past year were randomized to 14 days of (1) lansoprazole, 30 mg bid, plus amoxicillin, 1 gm tid; (2) lansoprazole, 30 mg tid, plus amoxicillin, 1 gm tid; (3) lansoprazole, 30 mg tid alone; or (4) amoxicillin, 1 gm tid alone. Endoscopy was done at enrollment and at 4 to 6 weeks after completion of treatment or for recurrent symptoms. H. pylori status was assessed by culture and histology. Ulcer prevalence was evaluated at follow-up endoscopy. Results. Two hundred sixty-two patients met enrollment criteria and were treated. By per-protocol analysis, H. pylori infection was cured in 57% of those treated with lansoprazole twice daily plus amoxicillin and in 67% of those treated with lansoprazole three times daily plus amoxicillin, compared with 0% treated with lansoprazole alone or amoxicillin alone (p < .001 for dual therapy versus either monotherapy). Amoxicillin resistance was not observed. At follow-up endoscopy, ulcer prevalence was 17% in patients treated with lansoprazole twice daily plus amoxicillin, 23% in those treated with lansoprazole three times daily plus amoxicillin, 33% in those treated with lansoprazole alone, and 35% in those treated with amoxicillin alone (p = .024; lansoprazole twice daily plus amoxicillin versus amoxicillin alone). Conclusions. Treatment with amoxicillin plus lansoprazole, 30 mg tid, led to cure of H. pylori infection in 67% of patients with active or recently healed duodenal ulcer.

Original languageEnglish (US)
Pages (from-to)243-250
Number of pages8
JournalHelicobacter
Volume1
Issue number4
StatePublished - 1996

Fingerprint

Lansoprazole
Amoxicillin
Helicobacter Infections
Helicobacter pylori
Therapeutics
Endoscopy
Omeprazole
Duodenal Ulcer
Ulcer

ASJC Scopus subject areas

  • Microbiology
  • Gastroenterology

Cite this

Harford, W., Lanza, F., Arora, A., Graham, D., Haber, M., Weissfeld, A., ... Siepman, N. (1996). Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. Helicobacter, 1(4), 243-250.

Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. / Harford, William; Lanza, Frank; Arora, Ajit; Graham, David; Haber, Marian; Weissfeld, Alice; Rose, Pamela; Siepman, Nancy.

In: Helicobacter, Vol. 1, No. 4, 1996, p. 243-250.

Research output: Contribution to journalArticle

Harford, W, Lanza, F, Arora, A, Graham, D, Haber, M, Weissfeld, A, Rose, P & Siepman, N 1996, 'Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection', Helicobacter, vol. 1, no. 4, pp. 243-250.
Harford, William ; Lanza, Frank ; Arora, Ajit ; Graham, David ; Haber, Marian ; Weissfeld, Alice ; Rose, Pamela ; Siepman, Nancy. / Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. In: Helicobacter. 1996 ; Vol. 1, No. 4. pp. 243-250.
@article{794d200dd9cf46e5bb151ea5bdd61520,
title = "Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection",
abstract = "Background. Treatment with amoxicillin plus omeprazole results in disappointing cure rates of Helicobacter pylori infection. The minimal inhibitory concentration of lansoprazole for H. pylori in vitro is lower than that for omeprazole, prompting interest in treatment with amoxicillin plus lansoprazole. Materials and Methods. H. pylori-infected patients with endoscopically documented duodenal ulcer either currently or within the past year were randomized to 14 days of (1) lansoprazole, 30 mg bid, plus amoxicillin, 1 gm tid; (2) lansoprazole, 30 mg tid, plus amoxicillin, 1 gm tid; (3) lansoprazole, 30 mg tid alone; or (4) amoxicillin, 1 gm tid alone. Endoscopy was done at enrollment and at 4 to 6 weeks after completion of treatment or for recurrent symptoms. H. pylori status was assessed by culture and histology. Ulcer prevalence was evaluated at follow-up endoscopy. Results. Two hundred sixty-two patients met enrollment criteria and were treated. By per-protocol analysis, H. pylori infection was cured in 57{\%} of those treated with lansoprazole twice daily plus amoxicillin and in 67{\%} of those treated with lansoprazole three times daily plus amoxicillin, compared with 0{\%} treated with lansoprazole alone or amoxicillin alone (p < .001 for dual therapy versus either monotherapy). Amoxicillin resistance was not observed. At follow-up endoscopy, ulcer prevalence was 17{\%} in patients treated with lansoprazole twice daily plus amoxicillin, 23{\%} in those treated with lansoprazole three times daily plus amoxicillin, 33{\%} in those treated with lansoprazole alone, and 35{\%} in those treated with amoxicillin alone (p = .024; lansoprazole twice daily plus amoxicillin versus amoxicillin alone). Conclusions. Treatment with amoxicillin plus lansoprazole, 30 mg tid, led to cure of H. pylori infection in 67{\%} of patients with active or recently healed duodenal ulcer.",
author = "William Harford and Frank Lanza and Ajit Arora and David Graham and Marian Haber and Alice Weissfeld and Pamela Rose and Nancy Siepman",
year = "1996",
language = "English (US)",
volume = "1",
pages = "243--250",
journal = "Helicobacter",
issn = "1083-4389",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection

AU - Harford, William

AU - Lanza, Frank

AU - Arora, Ajit

AU - Graham, David

AU - Haber, Marian

AU - Weissfeld, Alice

AU - Rose, Pamela

AU - Siepman, Nancy

PY - 1996

Y1 - 1996

N2 - Background. Treatment with amoxicillin plus omeprazole results in disappointing cure rates of Helicobacter pylori infection. The minimal inhibitory concentration of lansoprazole for H. pylori in vitro is lower than that for omeprazole, prompting interest in treatment with amoxicillin plus lansoprazole. Materials and Methods. H. pylori-infected patients with endoscopically documented duodenal ulcer either currently or within the past year were randomized to 14 days of (1) lansoprazole, 30 mg bid, plus amoxicillin, 1 gm tid; (2) lansoprazole, 30 mg tid, plus amoxicillin, 1 gm tid; (3) lansoprazole, 30 mg tid alone; or (4) amoxicillin, 1 gm tid alone. Endoscopy was done at enrollment and at 4 to 6 weeks after completion of treatment or for recurrent symptoms. H. pylori status was assessed by culture and histology. Ulcer prevalence was evaluated at follow-up endoscopy. Results. Two hundred sixty-two patients met enrollment criteria and were treated. By per-protocol analysis, H. pylori infection was cured in 57% of those treated with lansoprazole twice daily plus amoxicillin and in 67% of those treated with lansoprazole three times daily plus amoxicillin, compared with 0% treated with lansoprazole alone or amoxicillin alone (p < .001 for dual therapy versus either monotherapy). Amoxicillin resistance was not observed. At follow-up endoscopy, ulcer prevalence was 17% in patients treated with lansoprazole twice daily plus amoxicillin, 23% in those treated with lansoprazole three times daily plus amoxicillin, 33% in those treated with lansoprazole alone, and 35% in those treated with amoxicillin alone (p = .024; lansoprazole twice daily plus amoxicillin versus amoxicillin alone). Conclusions. Treatment with amoxicillin plus lansoprazole, 30 mg tid, led to cure of H. pylori infection in 67% of patients with active or recently healed duodenal ulcer.

AB - Background. Treatment with amoxicillin plus omeprazole results in disappointing cure rates of Helicobacter pylori infection. The minimal inhibitory concentration of lansoprazole for H. pylori in vitro is lower than that for omeprazole, prompting interest in treatment with amoxicillin plus lansoprazole. Materials and Methods. H. pylori-infected patients with endoscopically documented duodenal ulcer either currently or within the past year were randomized to 14 days of (1) lansoprazole, 30 mg bid, plus amoxicillin, 1 gm tid; (2) lansoprazole, 30 mg tid, plus amoxicillin, 1 gm tid; (3) lansoprazole, 30 mg tid alone; or (4) amoxicillin, 1 gm tid alone. Endoscopy was done at enrollment and at 4 to 6 weeks after completion of treatment or for recurrent symptoms. H. pylori status was assessed by culture and histology. Ulcer prevalence was evaluated at follow-up endoscopy. Results. Two hundred sixty-two patients met enrollment criteria and were treated. By per-protocol analysis, H. pylori infection was cured in 57% of those treated with lansoprazole twice daily plus amoxicillin and in 67% of those treated with lansoprazole three times daily plus amoxicillin, compared with 0% treated with lansoprazole alone or amoxicillin alone (p < .001 for dual therapy versus either monotherapy). Amoxicillin resistance was not observed. At follow-up endoscopy, ulcer prevalence was 17% in patients treated with lansoprazole twice daily plus amoxicillin, 23% in those treated with lansoprazole three times daily plus amoxicillin, 33% in those treated with lansoprazole alone, and 35% in those treated with amoxicillin alone (p = .024; lansoprazole twice daily plus amoxicillin versus amoxicillin alone). Conclusions. Treatment with amoxicillin plus lansoprazole, 30 mg tid, led to cure of H. pylori infection in 67% of patients with active or recently healed duodenal ulcer.

UR - http://www.scopus.com/inward/record.url?scp=0030309564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030309564&partnerID=8YFLogxK

M3 - Article

C2 - 9398875

AN - SCOPUS:0030309564

VL - 1

SP - 243

EP - 250

JO - Helicobacter

JF - Helicobacter

SN - 1083-4389

IS - 4

ER -